RPA
VRTX icon

Redwood Park Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Redwood Park Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$447 Sell
1
-1
-50% -$466 ﹤0.01% 273
2025
Q4 		$907 Hold
2
– – ﹤0.01% 251
2025
Q3 		$784 Sell
2
-1
-33% -$418 ﹤0.01% 263
2025
Q2 		$1.34K Hold
3
– – ﹤0.01% 231
2025
Q1 		$1.46K Hold
3
– – ﹤0.01% 252
2024
Q4 		$1.21K Buy
+3
New +$1.39K ﹤0.01% 259

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Redwood Park Advisors's VRTX Position: Q1 2026 in Review

Redwood Park Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 50% in Q1 2026, selling an estimated $466 and leaving 1 share worth $447. The position accounts for ﹤0.01% of the portfolio, ranked #273.

Redwood Park Advisors first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.46K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Redwood Park Advisors held 1 share of Vertex Pharmaceuticals worth $447 as of Q1 2026.
  • Redwood Park Advisors sold 1 Vertex Pharmaceuticals share in Q1 2026, an estimated $466.
  • Vertex Pharmaceuticals made up ﹤0.01% of Redwood Park Advisors's portfolio in Q1 2026, its #273 holding.
  • Redwood Park Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Redwood Park Advisors's Vertex Pharmaceuticals position peaked at $1.46K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Redwood Park Advisors's 13F filing for Q1 2026, filed 4 May 2026.